Journal of the Society for Integrative Oncology (J Soc Integr Oncol)

Publisher: Society for Integrative Oncology, Decker Publishing

Journal description

The Society for Integrative Oncology (SIO) is a non-profit, multi-disciplinary organization of professionals dedicated to studying and facilitating the cancer treatment and recovery process through the use of integrated complementary therapies. The mission of the SIO is to educate oncology professionals, patients, caregivers and relevant others about state-of-the-art integrative therapies, including their scientific validity, clinical benefits, toxicities, and limitations. SIO provides a forum for presentation, balanced discussion and peer review of evidence-based research in the discipline. The Journal of the Society for Integrative Oncology (JSIO) provides oncology professionals with need-to-know information about the data-based utility of complementary therapies. A broad range of topics will be presented by renowned international experts bridging numerous disciplines involved in cancer clinical care and research initiatives. The overall aim of JSIO is to facilitate dialogue within the oncology community and help broaden the approach to cancer treatment that integrative oncology can engender.

Current impact factor: 0.00

Impact Factor Rankings

Additional details

5-year impact 0.00
Cited half-life 0.00
Immediacy index 0.00
Eigenfactor 0.00
Article influence 0.00
Website Journal of the Society for Integrative Oncology website
Other titles Journal of the Society for Integrative Oncology (Online), JSIO
ISSN 1715-894X
OCLC 70220384
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Decker Publishing

  • Pre-print
    • Archiving status unclear
  • Post-print
    • Archiving status unclear
  • Conditions
    • We have contacted this publisher on multiple occasions, and have not been able to obtain a response to our enquiries. If you have any information on this publisher's policy, please submit an update using the form below.
  • Classification
    ‚Äč white

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: This study examined the effects of yoga on quality of life (QOL) and psychosocial outcomes in women with breast cancer undergoing radiotherapy. Sixty-one women were randomly assigned to either a yoga or a wait-list group. Yoga classes were taught biweekly during the 6 weeks of radiotherapy. Participants completed measures of QOL, fatigue, benefit finding (finding meaning in the cancer experience), intrusive thoughts, sleep disturbances, depressive symptoms, and anxiety before radiotherapy and then again 1 week, 1 month, and 3 months after the end of radiotherapy. General linear model analyses revealed that compared to the control group, the yoga group reported significantly better general health perception (p = .005) and physical functioning scores (p = .04) 1 week postradiotherapy; higher levels of intrusive thoughts 1 month postradiotherapy (p = .01); and greater benefit finding 3 months postradiotherapy (p = .01). There were no other group differences in other QOL subscales for fatigue, depression, or sleep scores. Exploratory analyses indicated that intrusive thoughts 1 month after radiotherapy were significantly positively correlated with benefit finding 3 months after radiotherapy (r = .36, p = .011). Our results indicated that the yoga program was associated with statistically and clinically significant improvements in aspects of QOL.
    Journal of the Society for Integrative Oncology 03/2010; 8(2):43-55. DOI:10.2310/7200.2010.0002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Current evidence indicates that acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) can provide sustained benefit for established radiation-induced xerostomia (RIX) symptoms. This is further being evaluated by comparing it with standard treatment (pilocarpine) in a randomized controlled trial. This report studies the potential effectiveness of xerostomia prevention using ALTENS delivered concomitantly with radiotherapy administered to head and neck cancer patients. Sixty patients were randomized to either the treatment group (n = 30) that received ALTENS daily with radiotherapy or the control group (n = 26) that had standard mouth care only. Stimulated and basal unstimulated whole saliva production (WSP) plus RIX symptoms visual analogue score (RIXVAS) were assessed at specific time points. Generalized linear models and generalized estimating equations were used for analysis. RIXVAS at 3 months follow-up after therapy completion was used as the primary study endpoint. The mean RIXVAS for the ALTENS intervention at 3 months was 39.8, which was not significantly different from the control arm value of 40.5. There were no statistically significant differences between the two groups for their mean RIXVAS and WSP at all assessment time points. In conclusion, there was no significant difference in mean WSP and RIXVAS between the two groups, so ALTENS is not recommended as a prophylactic intervention.
    Journal of the Society for Integrative Oncology 03/2010; 8(2):35-42. DOI:10.2310/7200.2009.0022
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this article is to share the lessons learned in forming an interdisciplinary team that implements a team science approach to integrative medicine (IM) research. The disciplines of nursing, statistics, and engineering, along with consultants and a reflexology practitioner, formed this university-based team to conceptualize and develop a prototype robotic device for reflexology for breast cancer patients. The nurse investigator contributed the intervention background and access to the population; the statistician guided the team thinking on factors that needed to be controlled for; the engineers provided the expertise in device design and development; consultants facilitated the team's thinking in new directions; and the reflexology practitioner prescribed the protocol. We discuss the contributions and achievements of each discipline, as well as the challenges, and share the team experiences with the intent to help guide the formation of new IM teams that promote a conducive atmosphere for carrying out cutting-edge IM research and advancing the science.
    Journal of the Society for Integrative Oncology 01/2010; 8(1):14-9.
  • Source
    Journal of the Society for Integrative Oncology 01/2010; 8(2):33-4.
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are important safety concerns associated with dietary supplements and foods rich in phytoestrogens, especially for breast cancer patients with hormone-sensitive disease. However, no consensus has been reached concerning specific dietary items that should be avoided, and safe levels of potentially problematic foods have yet to be determined. Excellent qualitative reviews of phytoestrogens and breast cancer have been published. These list agents that contain phytoestrogens and offer general cautions. Quantitative reviews, however, are needed but not yet available. Here we review quantitative data on phytoestrogens, their interaction with estrogen receptors, their bioavailability and pharmacokinetics, and their effects on breast cancer cells and animal models. We also note foods and botanicals with substances that interact with estrogen receptors and discuss the phytoestrogens they contain. Based on current evidence, we propose recommendations for advising breast cancer patients, which may also serve as a basis for the development of clinical practice guidelines.
    Journal of the Society for Integrative Oncology 01/2010; 8(1):20-30.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To examine the impact of random assignment to music versus usual care on anxiety, perceived pain level and patient satisfaction in patients undergoing bone marrow biopsies. Patients were randomized to music or usual care after completing a baseline questionnaire. All patients completed a post-procedure questionnaire. Study participants (N=59) had a mean age of 50.9 years (SD = 13.9; range 22-78). Post-procedure state anxiety (STAI) and pain rating (VAS) were not significantly different between groups (STAI p=0.766; VAS p=0.771). However, patient satisfaction with music was high; 66% of these patients said they very much preferred to listen to music at a future biopsy. While there were no significant group differences for the music intervention compared to standard of care for anxiety or perceived pain, additional feedback indicated that patients found the music intervention beneficial and requested use of music during future procedures.
    Journal of the Society for Integrative Oncology 01/2010; 8(4):140-147.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this survey was to examine patient-doctor communication about the use of complementary and alternative medicine (CAM) by adult patients with cancer and compare patients' satisfaction with the consultation between patients who had and those who had not discussed the use of CAM with their doctors. Oncologists from three hospitals screened patients for eligibility. Eligible patients were mailed a letter of invitation with a questionnaire (N = 1,323). Three hundred eighty-one questionnaires were returned. Sixty-five percent of cancer patients used at least one form of CAM. Use of CAM was not discussed with the oncologist by 55% of respondents using biologically based CAM and by 80% of those using non-biologically based CAM since the diagnosis of cancer. Patients who discussed the use of biologic CAM with their oncologists were more satisfied with the consultation than those who had not (p = .027), whereas there were no significant differences between patients who discussed or did not discuss use of non-biologically based CAM (p = .102). A substantial proportion of cancer patients do not discuss the use of CAM with their oncologists. It is important to improve patient-doctor communication about the use of CAM to increase patients' satisfaction with the oncology consultation.
    Journal of the Society for Integrative Oncology 01/2010; 8(2):56-64.
  • Journal of the Society for Integrative Oncology 01/2010; 8(1):1-2.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of a phase II trial is to determine whether an anticancer agent is sufficiently promising to take forward to a definitive, randomized, phase III study. Traditional phase II trials use tumor response as an end point, defined as a 50% or greater decrease in tumor size. Anticancer botanicals and supplements are unlikely to bring about rapid tumor regression, even if they do extend survival. Accordingly, response needs to be defined in terms of survival, such as being progression-free at 6 months. Such an approach requires historical data on the expected survival rate in the absence of the botanical or supplement. We present a simple phase II design for botanicals and supplements that is based on appropriate use of historical data, incorporating adjustment for both sampling variation and case mix. The basic principle is to use a historical cohort to generate a statistical prediction model, use this to predict results of patients in the phase II study, and then compare the predictions to the observed results. Such a design asks whether patients treated by the new agent are doing better than expected; if so, this suggests that the agent should be tested further in phase III trials.
    Journal of the Society for Integrative Oncology 02/2009; 7(1):35-40.
  • Source
    Journal of the Society for Integrative Oncology 02/2009; 7(1):1-3.